United Therapeutics Corporation Q3 FY2025 earnings call

Key Points - United Therapeutics had a strong quarter with record revenues and progress in the pipeline, including fully enrolling three Phase III trials and sharing unblinded results for pulmonary fibrosis with unprecedented benefits. - As a public benefit company, the company has invested in developing a robust product portfolio for pulmonary fibrosis, repurchased shares, and is guiding to a $4 billion revenue run rate by 2027. - Tyvaso DPI is showing strong growth with no material impact from YUTREPIA's launch, driven by dosing convenience, tolerability data, and favorable payer coverage decisions. The new 80-microgram cartridge and combination kits are set to enhance patient access. - The Remodulin segment launched the RemunityPRO pump, designed based on user feedback to improve the parenteral therapy experience. - The pipeline for ralinepag is progressing well with strong enrollment in outcomes trials and potential for combination therapies and formulation flexibility.

United Therapeutics reported total revenues of $800 million for the third quarter, representing a 7% growth from the third quarter of 2024. Tyvaso and Orenitram sales contributed to this growth. The Tyvaso DPI segment saw advancements with the upcoming launch of 80-microgram cartridges, 96 and 112-microgram combination kits, which aim to provide dosing convenience and affordability. Additionally, the Remodulin segment launched the new RemunityPRO pump, designed to enhance the patient experience with parenteral therapy. Revenue contribution details weren't explicitly broken down by segment percentage, but the focus was on the growth and innovations in Tyvaso and Remodulin.

Forward-Looking Statements - United Therapeutics is guiding to a $4 billion revenue run rate not later than 2027. - The company expects to hit a $1.5 billion revenue mark in 2027. - Confidence in continued growth of Tyvaso in both PAH and PH-ILD segments moving into 2026 and beyond.

Risks - While not extensively detailed in the transcript, typical risks associated with clinical trials, regulatory approvals, competition in the pharmaceutical market, and potential variability in patient adoption of new products and therapies are inherent. However, no specific detailed risk discussions were prominently featured in the provided transcript.

Q: Congrats on the quarter. Given the TETON 2 results in IPF, are you seeing an uptick in diagnoses of IPF patients with PH? And if so, do you think this could positively impact Tyvaso sales over the next few quarters?

A: Michael Benkowitz responded that physicians are interested in the TETON 2 data but it's too early to see an uptick as the data was unblinded recently; they are monitoring the situation closely.

Q: Congrats on another solid quarter. Martine, you mentioned in your remarks ralinepag and potential for combination. Can you give a sense of where you see the market opportunity for ralinepag and expectations for advanced outcomes next year?

A: Martine Rothblatt stated ralinepag is exceeding expectations with strong enrollment in outcomes trials, long patent life, synergy potential with other drugs, and formulation flexibility opening up various opportunities.

Q: Congrats on the progress. Martine, in addition to that combination partnership potential, it sounds like you also mentioned some large pharma partnership related to -- or in light of the recent Tyvaso IPF data. So maybe if you could go a little bit more into maybe what you're thinking about there? What would an ideal kind of partner look like or partnership? And is this related to kind of European rights?

A: Martine referred to Dr. Leigh Peterson to handle details on enrollment, mechanism of action, and regulatory aspects related to the partnership potential.

Q: Congrats for the record quarter again. One is on the PPF. So just curious about the data timing on the enrollment. And then more interesting question could be the -- given the TETON-2 data, how is the read-through to the IPF? Any new updated thoughts from physicians and scientists regarding the MOA? And then also quickly on IPF and the Phase II meeting, I believe you are having a meeting with the FDA around year-end. And then just curious about the potential outcome scenario, any upside case you can have earlier approval?

A: Dr. Leigh Peterson responded that PPF enrollment is halfway through, MOA has similarities due to fibrosis and disease progression, and the company is meeting with the FDA to discuss expediting regulatory review of IPF indications.

Q: So I wanted to ask about the 80-microgram cartridge for DPI. Could you give a little bit more color on the launch plans for that? Any strategies to drive more durable patient use, possible switching from the prior cartridge, et cetera?

A: Pat Poisson stated the 80-microgram cartridge will be launched soon, adding convenience as patients can now take 15 breaths in one dose instead of combining cartridges, aiming to enhance patient use and dosing durability.